Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 7Genitourinary 3Tumor-Agnostic 1Gynecologic 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Stage I Prostate Adenocarcinoma 1Prostatic Neoplasms 1

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Raloxifene Hydrochloride × Genitourinary × Clear all
NCT00710970 2022-01-24

Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment

Baylor College of Medicine

Phase 2 Completed
28 enrolled 8 charts
Genitourinary

Urinary Bladder Neoplasms

NCT03147196 2019-01-22

Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

Mayo Clinic

Phase 2 Withdrawn
Genitourinary

Stage I Prostate Adenocarcinoma

NCT01050842 2017-03-23

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

Mayo Clinic

Phase EARLY_PHASE1 Completed
18 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡